Patents by Inventor Bernard A. Fox

Bernard A. Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10597731
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 24, 2020
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 10597732
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: March 24, 2020
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 10226518
    Abstract: A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 12, 2019
    Assignees: UbiVac, LLC, Providence Health & Science—Oregon
    Inventors: Christopher Twitty, Erik LeShane, Bernard Fox, Hong-Ming Hu, Guangjie Yu
  • Publication number: 20180179598
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Application
    Filed: February 21, 2018
    Publication date: June 28, 2018
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Publication number: 20180171419
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 21, 2018
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 9920378
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: March 20, 2018
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 9318296
    Abstract: A cathode of a magnetron having a radial extension to accommodate the cathode terminals is supported by arms which have a greater diameter over the region in which they are supported in the glass thimble than over the region of the free ends. This shifts any vibrations to a higher frequency band, which is less liable to be excited in the event the magnetron is moved rapidly as in a linac used for radiotherapy purposes.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: April 19, 2016
    Assignee: E2V Technologies (UK) Limited
    Inventors: David Bernard Fox, Timothy Peter Fox, Scott Williams
  • Publication number: 20160076109
    Abstract: A method is presented for screening cells that produce allogeneic autophagosome enriched compositions able to induce expression of a selective marker on a subpopulation of peripheral blood mononuclear cells, the method comprising contacting a cell with a proteasome inhibitor, contacting the cell with a lysosome inhibitor, harvesting the resulting autophagosomes, determining a molecular signature of the harvested autophagosomes, and selecting cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes. By screening for cells that divert one or more Toll-like receptor agonist and/or one or more molecular chaperones to the harvested autophagosomes, enriched populations of autophagosomes may be generated which may illicit a specific immune response against numerous cancer types.
    Type: Application
    Filed: November 25, 2015
    Publication date: March 17, 2016
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Patent number: 9226955
    Abstract: A composition, comprising: an enriched population of autophagosomes derived from a non-small cell lung carcinoma cell line, and wherein the enriched population of autophagosomes includes: one or more toll-like receptor agonists; one or more tumor antigens; and one or more damage-associated molecular pattern molecules. In this way, an off-the-shelf vaccine may be available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: January 5, 2016
    Assignees: UbiVac, LLC, Providence Health & Services-Oregon
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Publication number: 20150104477
    Abstract: A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Inventors: Christopher Twitty, Erik LeShane, Bernard Fox, Hong-Ming Hu, Guangjie Yu
  • Patent number: 8810132
    Abstract: A magnetron has an anode and a cathode. The cathode includes two parts joined by sleeves of ferrous alloy spaced by a sleeve of insulating material. The ferrous alloy sleeves are adapted to be connected to opposite poles of a power supply for heating the cathode. A high frequency power supply is used to heat the cathode. The ferrous alloy sleeves have a surface coating of conductive material. The currents induced by the magnetic field generated by the high frequency currents of the power supply are largely confined to the conductive coating due to the skin effect, avoiding the heating of and losses in the ferrous alloy itself which would otherwise ensue.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: August 19, 2014
    Assignee: E2V Technologies (UK) Limited
    Inventors: David Bernard Fox, Robert Richardson
  • Publication number: 20140112977
    Abstract: A composition, comprising: an enriched population of autophagosomes derived from a non-small cell lung carcinoma cell line, and wherein the enriched population of autophagosomes includes: one or more toll-like receptor agonists; one or more tumor antigens; and one or more damage-associated molecular pattern molecules. In this way, an off-the-shelf vaccine may be available to be administered in order to stimulate a targeted immune response in patients bearing different tumor types.
    Type: Application
    Filed: October 23, 2013
    Publication date: April 24, 2014
    Inventors: Traci Hilton, Sandra Aung, Rieneke van de Ven, Christopher Paustian, Tarsem Moudgil, Christopher Dubay, Christopher Twitty, Hong-Ming Hu, Bernard A. Fox
  • Publication number: 20130221844
    Abstract: A high power electron tube, such as a magnetron, has the disadvantage that, to reduce the chances of the ceramic RF window failing in use, the manufacturing step entails a prolonged ageing period of powering the magnetron at low power on test, in order to drive any absorbed gases out of the RF window. According to the invention, the RF window 6 is internally glazed (8), which makes it possible to avoid the ageing period.
    Type: Application
    Filed: May 11, 2011
    Publication date: August 29, 2013
    Applicant: E2V Technologies (UK) Limited
    Inventor: David Bernard Fox
  • Publication number: 20130082594
    Abstract: A magnetron has an anode and a cathode. The cathode includes two parts joined by sleeves of ferrous alloy spaced by a sleeve of insulating material. The ferrous alloy sleeves are adapted to be connected to opposite poles of a power supply for heating the cathode. A high frequency power supply is used to heat the cathode. The ferrous alloy sleeves have a surface coating of conductive material. The currents induced by the magnetic field generated by the high frequency currents of the power supply are largely confined to the conductive coating due to the skin effect, avoiding the heating of and losses in the ferrous alloy itself which would otherwise ensue.
    Type: Application
    Filed: March 25, 2011
    Publication date: April 4, 2013
    Applicant: E2V Technologies (UK) Limited
    Inventors: David Bernard Fox, Robert Richardson
  • Publication number: 20120235564
    Abstract: A cathode of a magnetron having a radial extension to accommodate the cathode terminals is supported by arms which have a greater diameter over the region in which they are supported in the glass thimble than over the region of the free ends. This shifts any vibrations to a higher frequency band, which is less liable to be excited in the event the magnetron is moved rapidly as in a linac used for radiotherapy purposes.
    Type: Application
    Filed: March 19, 2012
    Publication date: September 20, 2012
    Applicant: E2V Technologies (UK) Limited
    Inventors: David Bernard Fox, Timothy Peter Fox, Scott Williams
  • Publication number: 20090317407
    Abstract: Methods are disclosed for stimulating an immune response against a target antigen, such as one or more tumor associated antigens. In particular examples the method includes reducing the number of CD4+ T cells in a subject after the subject receives a first dose of an immunogenic composition that includes the target antigen (such as a cancer vaccine), wherein the subject has a tumor that expresses the target antigen. The subject is administered a second dose of the immunogenic composition, thereby stimulating an immune response against the target antigen. In some examples the method also includes administering to the subject peripheral blood mononuclear cells (PBMCs) (for example a population of PBMCs depleted of CD25 cells, CD81 cells, CD134+ cells, Areg+ cells, Ptgr3+ cells, or combinations thereof) prior to receiving the first dose of the immunogenic composition.
    Type: Application
    Filed: May 2, 2007
    Publication date: December 24, 2009
    Inventors: Michael G. LaCelle, Bernard A. Fox, Shawn M. Jensen, Christian H. Poehlein
  • Patent number: 7221558
    Abstract: A high voltage switching apparatus delivers kV pulses to a load such as a magnetron. The switching apparatus comprises a switching stack surrounded by capacitors and both arranged within a housing. Lt power is supplied to the stack, e.g. for control electronics, by magnetic coupling across a non-conducting wall of the housing. Annular inserts are arranged on either side of the wall. Each insert receives a transformer core and winding. The bottom surfaces of the inserts carry a conductive coating to minimise electric stresses. Ht power is also supplied through the wall.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: May 22, 2007
    Assignee: E2V Technologies (UK) Limited
    Inventors: Stephen Mark Iskander, David Bernard Fox, Robert Richardson
  • Publication number: 20040190231
    Abstract: A high voltage switching apparatus delivers kV pulses to a load such as a magnetron. The switching apparatus comprises a switching stack surrounded by capacitors and both arranged within a housing. Lt power is supplied to the stack, e.g. for control electronics, by magnetic coupling across a non-conducting wall of the housing. Annular inserts are arranged on either side of the wall. Each insert receives a transformer core and winding. The bottom surfaces of the inserts carry a conductive coating to minimise electric stresses. Ht power is also supplied through the wall.
    Type: Application
    Filed: December 12, 2003
    Publication date: September 30, 2004
    Inventors: Stephen Mark Iskander, David Bernard Fox, Robert Richardson